Achtar drug price rise from $50 to $28,000 and impact

An article in the New York Times (December 30, 2012) describes the rise in price for a vial of the anti-inflammatory drug Achtar from $50 to $28,000. But patients who cannot pay given the drug free. The drug is off patent, but given its approval in the 1950s, new claims are not subject to rigorous FDA scrutiny. But the higher prices and 99% of selling price profits have improved availability and lowered prices for the poor. Is this shifting of prices to insurance companies a reasonable outcome? Should old drugs used for new treatments be forced to follow new rules? Or will the higher prices incentivize generics to rush in and thus drop prices?

About aviyer2010

Professor
This entry was posted in Service Operations, Supply Chain Issues and tagged , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s